Portal de Periódicos da CAPES

Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

2018; Impact Journals LLC; Volume: 9; Issue: 37 Linguagem: Inglês

10.18632/oncotarget.25324

1949-2553

Mohammad Hashemi, Gholamreza Bahari, Jarosław Markowski, Andrzej Małecki, Marek Łoś, Saeid Ghavami,

Childhood Cancer Survivors' Quality of Life

// Mohammad Hashemi 1, 2 , Gholamreza Bahari 2 , Jarosław Markowski 3 , Andrzej Małecki 4 , Marek J. Łos 5, 8 and Saeid Ghavami 6, 7 1 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran 2 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran 3 ENT Department, School of Medicine, Medical University of Silesia in Katowice, Katowice, Poland 4 Faculty of Physiotherapy, The Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland 5 Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Katowice, Poland 6 Department of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada 7 Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran 8 Centre de Biophysique Moléculaire, CNRS, Rue Charles Sadron, Orleans, France Correspondence to: Mohammad Hashemi, email: mhd.hashemi@gmail.com ; hashemim@zaums.ac.ir Marek J. Łos, email: bioappl@gmail.com Keywords: PDCD6; meta-analysis; cancer; risk; endometrial cancer Received: January 08, 2018 Accepted: April 12, 2018 Published: May 15, 2018 ABSTRACT This study was designed to evaluate the relationship between Programmed cell death protein 6 (PDCD6) polymorphisms and cancer susceptibility. The online databases were searched for relevant case-control studies published up to November 2017. Review Manage (RevMan) 5.3 was used to conduct the statistical analysis. The pooled odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate the strength of association. Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70–0.96, p = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39-0.72, p < 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66-0.89, p = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43-0.78, p = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67–0.86, p < 0.00001, G vs T) genetic model. The finding did not support an association between rs4957014 T>G polymorphism of PDCD6, and different cancers risk.